Merck is acquiring Cidara Therapeutics for 9.2 billion dollars.

Merck is nearing a $9.2 billion deal to acquire Cidara Therapeutics. This agreement is supported by Cidara Therapeutics' innovative work on a long-acting antibody drug. The drug is aimed at providing protection against infections and has also attracted market attention.

This strategic merger between Merck and Cidara Therapeutics is seen as a step that is expected to have significant effects in the biopharmaceutical field. Cidara Therapeutics' innovative approach has increased interest from investors and the healthcare sector.